Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasted to Post Q2 2024 Earnings of ($0.17) Per Share

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Analysts at HC Wainwright dropped their Q2 2024 EPS estimates for shares of Sangamo Therapeutics in a report issued on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings of ($0.17) per share for the quarter, down from their previous estimate of ($0.13). HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' Q3 2024 earnings at ($0.11) EPS, Q4 2024 earnings at ($0.06) EPS, FY2024 earnings at ($0.40) EPS, FY2025 earnings at ($0.09) EPS, FY2026 earnings at ($0.01) EPS and FY2027 earnings at $0.07 EPS.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The company had revenue of $0.48 million for the quarter, compared to analyst estimates of $8.51 million. Sangamo Therapeutics had a negative return on equity of 182.55% and a negative net margin of 1,749.06%. During the same period last year, the firm earned $0.12 EPS.

Several other equities research analysts also recently issued reports on SGMO. StockNews.com began coverage on shares of Sangamo Therapeutics in a research note on Saturday, April 27th. They issued a "sell" rating for the company. Royal Bank of Canada reissued a "sector perform" rating and set a $2.00 target price on shares of Sangamo Therapeutics in a report on Thursday, March 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Sangamo Therapeutics has a consensus rating of "Hold" and a consensus price target of $5.67.

Sangamo Therapeutics Price Performance

NASDAQ SGMO traded up $0.04 on Friday, hitting $0.65. 4,942,875 shares of the stock were exchanged, compared to its average volume of 2,159,006. The business's fifty day moving average is $0.62 and its 200 day moving average is $0.59. Sangamo Therapeutics has a 52 week low of $0.29 and a 52 week high of $1.67. The company has a market capitalization of $134.80 million, a PE ratio of -0.33 and a beta of 1.40.

Institutional Trading of Sangamo Therapeutics

A number of institutional investors have recently bought and sold shares of the business. State Board of Administration of Florida Retirement System raised its stake in Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 23,650 shares in the last quarter. Mackenzie Financial Corp raised its position in Sangamo Therapeutics by 72.4% during the fourth quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company's stock valued at $40,000 after purchasing an additional 31,003 shares in the last quarter. Golden State Equity Partners lifted its stake in Sangamo Therapeutics by 21.0% during the fourth quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company's stock worth $109,000 after purchasing an additional 34,960 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Sangamo Therapeutics in the 3rd quarter valued at $26,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Sangamo Therapeutics by 10.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 676,189 shares of the biopharmaceutical company's stock valued at $406,000 after purchasing an additional 62,465 shares during the last quarter. Institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.